Novartis cuts ties with Mesoblast's failed COVID-19 cell therapy as biotech tries for pivotal phase 3 Boston Scientific to lay off 170 workers, close Silicon Valley manufacturing plant The top 10 healthcare M&A deals of 2021 CSL to buy Vifor for $11.7B in biopharma's largest M&A deal this year Turns out Galera's radiotherapy complication drug did work after all, and investors are thrilled Centene mulls divestiture of $2B international business as part of value creation effort Pfizer's COVID-19 antiviral is expected to work against the omicron variant Philips gets the blood flowing with Vesper Medical vascular tuck-in buy Idorsia hoping to make its dreams come true with a new insomnia alliance Fujifilm beefs up US biologics capacity with $300M Texas outlay, corrals 150 new jobs Generation Bio shares halved as hemophilia gene therapy hunt goes back to square one Senate version of Build Back Better axes DSH cuts to hospitals in non-expansion states FDA panel rejects BrainsGate neurostimulation implant for ischemic stroke Insurtech platform HealthCare.com banks $180M, boosts valuation to $1B Sanofi's hemophilia hopeful reduces bleeds in phase 3 studies, but adverse events persist Featured Story | By Kyle LaHucik Novartis has canceled an agreement with Mesoblast on a failed COVID-19 cell therapy just as the Australian biotech tries to get a new phase 3 trial off the ground in the hopes the FDA will give the candidate another shot. read more |
| |
|---|
|
|
| The PerkinElmer Biotech Bundle: advanced chemical and biologic data analytic software that represents complex data so key relationships can be better understood and decisions made with increased confidence. Learn more. |
Top Stories By Andrea Park The manufacturing facility's closure and subsequent layoffs will take effect Jan. 30. read more By Heather Landi Healthcare merger and acquisition activity hit a new stride in 2021, fueled by investor interest in digital health and virtual care as well as the SPAC craze that's pumping a lot of cash into the market. read more By Kevin Dunleavy In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vaccines and blood plasma products—Vifor’s attractive kidney disease and iron deficiency franchises. read more By Annalee Armstrong Galera’s shares were pummeled in the wake of news that its radiotherapy complication drug flunked a phase 3 study, but now the biotech says the study results were in error, and the treatment did, in fact, work. read more By Paige Minemyer As part of its ongoing examination of its portfolio, Centene Corporation is "evaluating strategic alternatives" for its businesses abroad. read more By Annalee Armstrong Pfizer said it expects its antiviral pill Paxlovid to provide protection against the omicron variant of the coronavirus, amid worldwide concern that existing medications and vaccines would not work against the newly mutated version. read more By Conor Hale Philips is looking to bolster its vascular franchise by absorbing Vesper Medical, maker of stents designed to open up blocked or narrowed veins in the legs. read more By Ben Adams Sleepless nights are nothing new to most people, but chronic insomnia takes this to another level. Idorsia, awaiting an FDA approval for its sleep drug, has set up an alliance to research the condition. read more By Fraiser Kansteiner Fujifilm Diosynth Biotechnologies is splashing out $300 million to build a new production facility at its single-use manufacturing campus in College Station, Texas, the company said Tuesday. Alongside a major biologics capacity upgrade, the expansion is set to add 150 new jobs by 2024—the same year that the new facility is expected to come online. read more By Annalee Armstrong Generation Bio’s shares were briefly halted Tuesday morning on the release of mouse data that complicated its search for a viable target for hemophilia A to take into the clinic. read more By Robert King A newly released version of the Build Back Better Act nixes cuts to disproportionate share hospital payments to facilities in states that did not expand Medicaid. read more By Andrea Park Nearly two years after BrainsGate submitted its implantable neurostimulation device for FDA premarket approval, an advisory panel for the agency struck a major blow to the Israeli company’s plans. read more By Rebecca Torrence HealthCare.com, which connects consumers with health plans, is now a unicorn after closing a $180 million round that boosted its valuation to more than $1 billion. read more By Kyle LaHucik Sanofi's hemophilia drug, put on pause last year, could be closer to the FDA's doorstep on new late-stage data that shows the treatment significantly reduced bleeds. But the adverse events that raised red flags are still persisting in one study. read more | 